A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
=== Isomerisation === In dilute sodium hydroxide or other dilute bases, the monosaccharides mannose, glucose, and fructose interconvert (via a Lobry de Bruyn–Alberda–Van Ekenstein transformation), so that a balance between these isomers is formed. This reaction proceeds via an enediol:
Transdermal progesterone is usually supplied in the form of creams and water-based gels, and the studies in which very low levels of progesterone in circulation were observed with transdermal progesterone used these formulations. One study of 100 mg/day transdermal progesterone in the form of an alcohol-based gel found relatively high concentrations of progesterone in circulation that corresponded to luteal-phase levels. The peak levels of progesterone were 8 ng/mL and were theoretically sufficient to confer endometrial protection. These findings, although based on a single study, suggest that alcohol-based progesterone gels might yield relatively high levels of circulating progesterone. One possible explanation for the difference is that progesterone creams are more lipophilic and may have a preference for uptake into the fatty layer under the skin. Conversely, alcohol-based gels are more water-soluble and may rapidly distribute into the microcirculation of the skin and then into the general circulation. However, in another study that investigated the pharmacokinetics of transdermal progesterone using either a hydrophilic-, lipophilic-, or emulsion-type base, it was found that in all three cases that the time to peak concentrations was around 4 hours and the venous blood levels observed were very low.
=== 17 March === The United Nations said the RSF detained more than 60 peacekeepers, abducted eight civilian staff, and seized eight vehicles and 280,000 litres of fuel from a United Nations Interim Security Force for Abyei (UNISFA) logistics convoy heading from a refueling mission in Kadugli.
=== Policy and advocacy === Laposata served on the Institute of Medicine Committee on Diagnostic Error in Health Care. The committee produced the 2015 report Improving Diagnosis in Health Care.[5] In August 2024 he served the Association for Molecular Pathology as a plaintiff in a lawsuit challenging the FDA's final rule on regulating laboratory developed tests.[2][4] In 2025 a federal district court in Texas vacated the rule.[4] That November, the Association for Molecular Pathology gave him its Champion for Innovation Award for his role in the case.[2]
Cyanobactins are diverse metabolites from cyanobacteria with N-to-C macrocylization of a 6–20 amino acid chain. Cyanobactins are natural products isolated from cyanobacteria, and close to 30% of all cyanobacterial strains are thought to contain cyanobacterial gene clusters. However, while thus far all cyanobactins are credited to cyanobacteria, there exists the possibility that other organisms could produce similar natural products. The precursor peptide of the cyanobactin family is traditionally designated the "E" gene, whereas precursor peptides are designated gene "A" in most RiPP gene clusters. "A" is a serine protease involved in cleavage of the leader peptide and subsequent macrocyclization of the peptide natural product, in combination with an additional serine protease homologue, the encoded by gene "G". Members of the cyanobactin family may bear thiazolines/oxazolines, thiazoles/oxazoles, and methylations depending on additional modification enzymes. For example, perhaps the most famous cyanobactin is patellamide A, which contains two thiazoles, a methyloxazoline, and an oxazoline in its final state, a macrocycle derived from 8 amino acids.
Sources: en.wikipedia.org
=== Pharmacokinetics === Vilazodone is best absorbed with food and has a bioavailability of 72% under fed conditions. The Cmax increased between 147 and 160% and the AUC increased between 64 and 85% of vilazodone when it was administered with either a fatty or light meal.
Reform UK announces plans to cut government spending by £20bn a year if elected to government, with their plans including removing the right to claim benefits from EU citizens. 19 November – BBC News suggests that Labour MP Clive Lewis offered to give up his Norwich South constituency to allow Andy Burnham to return to the House of Commons, paving the way for Burnham to challenge Keir Starmer for the party's leadership, although they also say that Lewis later told The Sun that he had "no plans to stand down". Laura Anne Jones is suspended from the Senedd chamber for 14 days for breaking the parliamentary code over her use of a racial slur in a WhatsApp message. The Guardian reports allegations that, as a child almost 50 ago, Reform's Nigel Farage made anti-Semitic comments and taught younger pupils at Dulwich College racist songs. The paper also reports that other former pupils who know Farage said that they do not recall the behaviour described. Farage denied making any of the comments that were attributed to him. Andrew Polson, the former leader of Dunbartonshire Council, is sentenced to 22 months in prison for a £188,000 romance fraud. 20 November – COVID-19 in the UK: The second report to be released by the COVID-19 Inquiry summarises the UK's response to the pandemic as "too little, too late", and says lockdown may have been unnecessary if steps such as social distancing and the isolation of those with symptoms along with members of their household had been brought in earlier than mid-March 2020. Former Labour MP Lloyd Russell-Moyle defects to the Greens.
=== Drug reactions === Certain medications, including semaglutide, amiodarone and phosphodiesterase type 5 (PDE5) inhibitors like sildenafil (Viagra, the firstline treatment for erectile dysfunction), have been associated with NAION-like symptoms, including optic disc swelling and hemorrhages. The relationship between these medications and vision loss remains unclear due to the evidence being anecdotal, the lack of clear dose-response relationship, and co-existing risk factors. Clinical studies suggest a temporal increase in AION risk following PDE5 inhibitor use, leading to recommendations against their use in NAION affected individuals.
=== Labeling === For US food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For riboflavin labeling purposes 100% of the Daily Value was 1.7 mg, but as of 27 May 2016, it was revised to 1.3 mg to bring it into agreement with the RDA. A table of the old and new adult daily values is provided at Reference Daily Intake.
As the first woman since 1964 to win the Nobel Prize in chemistry, and the first since Dorothy Crowfoot Hodgkin, 45 years previously. She was also the fourth of eight women ever to win the Nobel Prize in chemistry. Although Yonath once remarked, “I am a scientist, not male or female. A scientist,” her 2009 award was noted as a highlight for female scientists. The Australian noted that Yonath's Nobel win was "crushing the lab's glass ceiling". Regarded as an influential Israeli scientist, Yonath helped established the first protein crystallography laboratory in Israel. In 2018, while interviewing Yonath, UNESCO noted that her scientific research has also been "key to understanding how antibiotics work". Following her death, The New York Times noted that Yonath's mapping of the ribosome led to new designs for antibiotics. Her work was noted as "boundary pushing" with it having "immediate and practical consequences" for medicine and in the "fight against infectious disease". President Isaac Herzog noted Yonath as "one of the leading researchers in the history of Israeli science". The Hindu also noted Yonath's academic impact, especially in India through her engagements in academic institutions in the country.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.